Lederle
Executive Summary
States that the price of the Elan ProStep nicotine patch which it markets in the U.S. is "within pennies" of the prices of Ciba- Geigy's Habitrol and Alza/Marion Merrell Dow's Nicoderm patches. The company takes issue with a statement in "The Pink Sheet" that ProStep will cost consumers about $4 per day, while the other nicotine patches will cost about $3 per day ("The Pink Sheet" Feb. 3, T&G-2). Ciba-Geigy has revised its estimated price for consumers to around $4 per day, while Marion Merrell Dow maintains that Nicoderm therapy will cost between $3 and $3.50 per day.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: